Gustavo E Velásquez1,2, Meredith B Brooks2, Julia M Coit2, Henry Pertinez3,4, Dante Vargas Vásquez5, Epifanio Sánchez Garavito6, Roger I Calderón7, Judith Jiménez7, Karen Tintaya7, Charles A Peloquin8, Elna Osso2, Dylan B Tierney9, Kwonjune J Seung9,10, Leonid Lecca2,7, Geraint R Davies3,4, Carole D Mitnick9,2,10. 1. 1 Division of Infectious Diseases and. 2. 2 Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts. 3. 3 Institute of Infection and Global Health and. 4. 4 Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom. 5. 5 Hospital Nacional Hipólito Unanue, Lima, Peru. 6. 6 Hospital Nacional Sergio Bernales, Lima, Peru. 7. 7 Partners in Health/Socios en Salud Sucursal Peru, Lima, Peru. 8. 8 College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, Florida; and. 9. 9 Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts. 10. 10 Partners in Health, Boston, Massachusetts.
Abstract
RATIONALE: We examined whether increased rifampin doses could shorten standard therapy for tuberculosis without increased toxicity. OBJECTIVES: To assess the differences across three daily oral doses of rifampin in change in elimination rate of Mycobacterium tuberculosis in sputum and frequency of rifampin-related adverse events. METHODS: We conducted a blinded, randomized, controlled phase 2 clinical trial of 180 adults with new smear-positive pulmonary tuberculosis, susceptible to isoniazid and rifampin. We randomized 1:1:1 to rifampin at 10, 15, and 20 mg/kg/d during the intensive phase. We report the primary efficacy and safety endpoints: change in elimination rate of M. tuberculosis log10 colony-forming units and frequency of grade 2 or higher rifampin-related adverse events. We report efficacy by treatment arm and by primary (area under the plasma concentration-time curve [AUC]/minimum inhibitory concentration [MIC]) and secondary (AUC) pharmacokinetic exposure. MEASUREMENTS AND MAIN RESULTS: Each 5-mg/kg/d increase in rifampin dose resulted in differences of -0.011 (95% confidence interval, -0.025 to +0.002; P = 0.230) and -0.022 (95% confidence interval, -0.046 to -0.002; P = 0.022) log10 cfu/ml/d in the modified intention-to-treat and per-protocol analyses, respectively. The elimination rate in the per-protocol population increased significantly with rifampin AUC0-6 (P = 0.011) but not with AUC0-6/MIC99.9 (P = 0.053). Grade 2 or higher rifampin-related adverse events occurred with similar frequency across the three treatment arms: 26, 31, and 23 participants (43.3%, 51.7%, and 38.3%, respectively) had at least one event (P = 0.7092) up to 4 weeks after the intensive phase. Treatment failed or disease recurred in 11 participants (6.1%). CONCLUSIONS: Our findings of more rapid sputum sterilization and similar toxicity with higher rifampin doses support investigation of increased rifampin doses to shorten tuberculosis treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01408914) .
RCT Entities:
RATIONALE: We examined whether increased rifampin doses could shorten standard therapy for tuberculosis without increased toxicity. OBJECTIVES: To assess the differences across three daily oral doses of rifampin in change in elimination rate of Mycobacterium tuberculosis in sputum and frequency of rifampin-related adverse events. METHODS: We conducted a blinded, randomized, controlled phase 2 clinical trial of 180 adults with new smear-positive pulmonary tuberculosis, susceptible to isoniazid and rifampin. We randomized 1:1:1 to rifampin at 10, 15, and 20 mg/kg/d during the intensive phase. We report the primary efficacy and safety endpoints: change in elimination rate of M. tuberculosis log10 colony-forming units and frequency of grade 2 or higher rifampin-related adverse events. We report efficacy by treatment arm and by primary (area under the plasma concentration-time curve [AUC]/minimum inhibitory concentration [MIC]) and secondary (AUC) pharmacokinetic exposure. MEASUREMENTS AND MAIN RESULTS: Each 5-mg/kg/d increase in rifampin dose resulted in differences of -0.011 (95% confidence interval, -0.025 to +0.002; P = 0.230) and -0.022 (95% confidence interval, -0.046 to -0.002; P = 0.022) log10 cfu/ml/d in the modified intention-to-treat and per-protocol analyses, respectively. The elimination rate in the per-protocol population increased significantly with rifampin AUC0-6 (P = 0.011) but not with AUC0-6/MIC99.9 (P = 0.053). Grade 2 or higher rifampin-related adverse events occurred with similar frequency across the three treatment arms: 26, 31, and 23 participants (43.3%, 51.7%, and 38.3%, respectively) had at least one event (P = 0.7092) up to 4 weeks after the intensive phase. Treatment failed or disease recurred in 11 participants (6.1%). CONCLUSIONS: Our findings of more rapid sputum sterilization and similar toxicity with higher rifampin doses support investigation of increased rifampin doses to shorten tuberculosis treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01408914) .
Authors: Frik A Sirgel; P Bernard Fourie; Peter R Donald; Nesri Padayatchi; Roxana Rustomjee; Jonathan Levin; Giorgio Roscigno; Jennifer Norman; Helen McIlleron; Denis A Mitchison Journal: Am J Respir Crit Care Med Date: 2005-04-01 Impact factor: 21.405
Authors: A Jindani; G Borgulya; I Westermann de Patiño; T Gonzales; R A de Fernandes; B Shrestha; D Atwine; M Bonnet; M Burgos; F Dubash; N Patel; A M Checkley; T S Harrison; D Mitchison Journal: Int J Tuberc Lung Dis Date: 2016-06 Impact factor: 2.373
Authors: Jotam G Pasipanodya; Helen McIlleron; André Burger; Peter A Wash; Peter Smith; Tawanda Gumbo Journal: J Infect Dis Date: 2013-07-29 Impact factor: 5.226
Authors: William J Burman; Stefan Goldberg; John L Johnson; Grace Muzanye; Melissa Engle; Ann W Mosher; Shurjeel Choudhri; Charles L Daley; Sonal S Munsiff; Zhen Zhao; Andrew Vernon; Richard E Chaisson Journal: Am J Respir Crit Care Med Date: 2006-05-04 Impact factor: 21.405
Authors: Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian Journal: Antimicrob Agents Chemother Date: 2003-07 Impact factor: 5.191
Authors: Elizabeth W Tucker; Beatriz Guglieri-Lopez; Alvaro A Ordonez; Brittaney Ritchie; Mariah H Klunk; Richa Sharma; Yong S Chang; Julian Sanchez-Bautista; Sarah Frey; Martin A Lodge; Steven P Rowe; Daniel P Holt; Jogarao V S Gobburu; Charles A Peloquin; William B Mathews; Robert F Dannals; Carlos A Pardo; Sujatha Kannan; Vijay D Ivaturi; Sanjay K Jain Journal: Sci Transl Med Date: 2018-12-05 Impact factor: 17.956
Authors: E D Pieterman; S van den Berg; A van der Meijden; E M Svensson; H I Bax; J E M de Steenwinkel Journal: Antimicrob Agents Chemother Date: 2021-03-18 Impact factor: 5.191
Authors: Krishna P Reddy; C Robert Horsburgh; Robin Wood; Naomi F Fields; Michael P Girouard; Sydney Costantini; Taige Hou; Kenneth A Freedberg; Rochelle P Walensky Journal: Ann Am Thorac Soc Date: 2020-02
Authors: Alvaro A Ordonez; Hechuan Wang; Gesham Magombedze; Camilo A Ruiz-Bedoya; Shashikant Srivastava; Allen Chen; Elizabeth W Tucker; Michael E Urbanowski; Lisa Pieterse; E Fabian Cardozo; Martin A Lodge; Maunank R Shah; Daniel P Holt; William B Mathews; Robert F Dannals; Jogarao V S Gobburu; Charles A Peloquin; Steven P Rowe; Tawanda Gumbo; Vijay D Ivaturi; Sanjay K Jain Journal: Nat Med Date: 2020-02-17 Impact factor: 53.440
Authors: Charlotte Seijger; Wouter Hoefsloot; Inge Bergsma-de Guchteneire; Lindsey Te Brake; Jakko van Ingen; Saskia Kuipers; Reinout van Crevel; Rob Aarnoutse; Martin Boeree; Cecile Magis-Escurra Journal: PLoS One Date: 2019-03-14 Impact factor: 3.240